Q1 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
Novartis off to a solid start in Q1 across our value drivers
Growth
Group sales +5% cc
IM sales +4% CC
Sandoz sales +8% cc
Productivity
Group core operating income +9% cc
IM core operating income +5% CC
IM core margin 35.9% (+0.2%pts) cc
Sandoz core operating income +26% cc
1
Innovation
3
PluvictoⓇ mCRPC post-taxane approved in US
VijoiceⓇ PROS approved in US1
BeovuⓇ DME approved in EU
KymriahⓇ r/r follicular lymphoma EU/EEA CHMP positive opinion
JDQ443 encouraging early clinical data from Ph1b KontRASt-01 study¹
2
ESG
4
AMR: extension / expansion of collaboration agreement with Ares
Genetics, enabling genomic surveillance for resistant pathogens¹
Access: agreements signed in Zambia, Tanzania (e.g. SCD, HF, HTN)
Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 35 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. IM - Innovative Medicines
division. 1. Post quarter event.
4 Investor Relations | Q1 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation